Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 21, 2012 - Issue 8
Submit an article Journal homepage
723
Views
13
CrossRef citations to date
0
Altmetric
Reviews

Immunomodulatory agents in myelofibrosis

Ali TabarrokiTaussig Cancer Institute, Cleveland Clinic, Department of Translational Hematology and Oncology Research, Cleveland, OH, USA
&
Ramon V TiuTaussig Cancer Institute, Cleveland Clinic, Department of Translational Hematology and Oncology Research, 9500 Euclid Avenue R40, Cleveland, OH 44195, USA+1 216 444 6730; +1 216 636 2498; [email protected];Taussig Cancer Institute, Cleveland Clinic, Department of Hematologic Oncology and Blood Disorders, Cleveland, OH, USA
, MD
Pages 1141-1154 | Published online: 06 Jun 2012

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Andrea Duminuco, Calogero Vetro, Cesarina Giallongo & Giuseppe Alberto Palumbo. (2023) The pharmacotherapeutic management of patients with myelofibrosis: looking beyond JAK inhibitors. Expert Opinion on Pharmacotherapy 24:13, pages 1449-1461.
Read now
Ali Tabarroki, Yogen Saunthararajah, Valeria Visconte, Tracy Cinalli, Kristin Colaluca, Heesun J. Rogers, Mikkael A. Sekeres, Hien K. Duong, Brady L. Stein & Ramon V. Tiu. (2015) Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts. Leukemia & Lymphoma 56:2, pages 497-499.
Read now
Claire N Harrison & Michael Bennett. (2014) Orphan drugs for myelofibrosis. Expert Opinion on Orphan Drugs 2:4, pages 391-405.
Read now

Articles from other publishers (10)

Yujin Li, Shirong Zhu, Weiyi Liu, Jing Ming, Xueying Wang & Xiaomei Hu. (2020) Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to. Annals of Hematology 99:6, pages 1161-1176.
Crossref
Petra Bělohlávková, Vladimír Maisnar, Jaroslava Voglová, Tomáš Buchler & Pavel Žák. (2016) Improvement of Anaemia in Patients with Primary Myelofibrosis by Low-Dose Thalidomide and Prednisone. Acta Medica (Hradec Kralove, Czech Republic) 59:2, pages 50-53.
Crossref
Giovanni Barosi. (2015) Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis. Current Hematologic Malignancy Reports 10:4, pages 362-369.
Crossref
Srdan VerstovsekSrdan Verstovsek & Kate J Newberry. 2015. Novel Insights into Myelofibrosis Pathophysiology and Treatment. Novel Insights into Myelofibrosis Pathophysiology and Treatment 104 122 .
G Barosi, A Tefferi, C Besses, G Birgegard, F Cervantes, G Finazzi, H Gisslinger, M Griesshammer, C Harrison, R Hehlmann, S Hermouet, J-J Kiladjian, N Kröger, R Mesa, M F Mc Mullin, A Pardanani, F Passamonti, J Samuelsson, A M Vannucchi, A Reiter, R T Silver, S Verstovsek, G Tognoni & T Barbui. (2014) Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT). Leukemia 29:1, pages 20-26.
Crossref
A Tabarroki, D J Lindner, V Visconte, L Zhang, H J Rogers, Y Parker, H K Duong, A Lichtin, M E Kalaycio, M A Sekeres, S E Mountantonakis, G A Heresi & R V Tiu. (2014) Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis. Leukemia 28:7, pages 1486-1493.
Crossref
John Mascarenhas. (2014) Rationale for combination therapy in myelofibrosis. Best Practice & Research Clinical Haematology 27:2, pages 197-208.
Crossref
Stephan Lindsey & Ramon V. Tiu. 2014. The Coagulation Consult. The Coagulation Consult 133 150 .
Paola Guglielmelli & Alessandro M. Vannucchi. (2013) Struggling with myelofibrosis-associated anemia. Leukemia Research 37:11, pages 1429-1431.
Crossref
Edy Hasrouni, Heesun J Rogers, Ali Tabarroki, Valeria Visconte, Fabiola Traina, Manuel Afable, Mikkael A Sekeres, Jaroslaw P Maciejewski & Ramon V Tiu. (2013) A case of mistaken identity: When lupus masquerades as primary myelofibrosis. SAGE Open Medical Case Reports 1, pages 2050313X1349870.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.